[go: up one dir, main page]

NO20032581L - Pharmaceutical formulation of gepirone for oral administration - Google Patents

Pharmaceutical formulation of gepirone for oral administration

Info

Publication number
NO20032581L
NO20032581L NO20032581A NO20032581A NO20032581L NO 20032581 L NO20032581 L NO 20032581L NO 20032581 A NO20032581 A NO 20032581A NO 20032581 A NO20032581 A NO 20032581A NO 20032581 L NO20032581 L NO 20032581L
Authority
NO
Norway
Prior art keywords
gepirone
amount
weight
oral administration
certain amount
Prior art date
Application number
NO20032581A
Other languages
Norwegian (no)
Other versions
NO20032581D0 (en
Inventor
Johannes Gerardus Jos Egberink
John Francis Gelhart
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO20032581D0 publication Critical patent/NO20032581D0/en
Publication of NO20032581L publication Critical patent/NO20032581L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Denne oppfinnelse tilveiebringer et farmasøytisk preparat for oral administrering, med langvarig frigjøring, omfattende en viss mengde gepironhydroklorid, en viss mengde av en cellulosepolymermatriks og en viss mengde mikrokrystallinsk cellulose, kjennetegnet ved at mengden av den farmasøytisk akseptable cellulosepolymermatriks er fra 70 til 85 vekt%, mengden av karbohydratbindemiddel er fra 7 til 10 vekt% og mengden av gepironhydroklorid er fra 13 til 21 vekt%. Preparatet er anvendelig for behandling av depresjon eller en beslektet sentramervessternforstyrrelse med gepiron administrert i et oralpreparat for tilføring én gang daglig, for langvarig frigjøring av gepiron.This invention provides a pharmaceutical composition for oral administration, with sustained release, comprising a certain amount of gepirone hydrochloride, a certain amount of a cellulose polymer matrix and a certain amount of microcrystalline cellulose, characterized in that the amount of the pharmaceutically acceptable cellulose polymer matrix is from 70 to 85% by weight. the amount of carbohydrate binder is from 7 to 10% by weight and the amount of gepirone hydrochloride is from 13 to 21% by weight. The composition is useful for the treatment of depression or a related central nervous system disorder with gepirone administered in an oral preparation for administration once daily, for prolonged release of gepirone.

NO20032581A 2000-12-08 2003-06-06 Pharmaceutical formulation of gepirone for oral administration NO20032581L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00204388 2000-12-08
PCT/EP2001/014189 WO2002045753A2 (en) 2000-12-08 2001-11-30 Oral extended release formulation of gepirone

Publications (2)

Publication Number Publication Date
NO20032581D0 NO20032581D0 (en) 2003-06-06
NO20032581L true NO20032581L (en) 2003-06-06

Family

ID=8172397

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032581A NO20032581L (en) 2000-12-08 2003-06-06 Pharmaceutical formulation of gepirone for oral administration

Country Status (19)

Country Link
EP (1) EP1343504A2 (en)
JP (1) JP2004517083A (en)
KR (1) KR20040018314A (en)
CN (1) CN1479620A (en)
AR (1) AR031461A1 (en)
AU (1) AU2002226371A1 (en)
BR (1) BR0115976A (en)
CA (1) CA2436692A1 (en)
CZ (1) CZ20031589A3 (en)
EC (1) ECSP034627A (en)
HU (1) HUP0401021A2 (en)
IL (1) IL155855A0 (en)
MX (1) MXPA03005099A (en)
NO (1) NO20032581L (en)
PL (1) PL362445A1 (en)
RU (1) RU2003120446A (en)
SK (1) SK6942003A3 (en)
WO (1) WO2002045753A2 (en)
ZA (1) ZA200303915B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003274110A1 (en) * 2002-09-24 2004-04-19 Akzo Nobel N.V. Method to improve pharmaceutical tablets having a matrix of cellulose ether
EP1809255A4 (en) * 2004-11-05 2011-08-03 Fabre Kramer Holdings Inc High-dosage extended-release formulation of gepirone
MY198454A (en) * 2017-07-26 2023-08-29 Abbott Lab Nutritional Tablets and Methods of Making the Same
CN109745323A (en) * 2017-11-01 2019-05-14 四川科瑞德制药股份有限公司 Azapirone compound improves the active purposes of parasympathetic nerve

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form

Also Published As

Publication number Publication date
NO20032581D0 (en) 2003-06-06
BR0115976A (en) 2003-12-30
CN1479620A (en) 2004-03-03
WO2002045753A3 (en) 2002-08-29
EP1343504A2 (en) 2003-09-17
ECSP034627A (en) 2004-09-28
MXPA03005099A (en) 2004-02-12
ZA200303915B (en) 2004-08-20
WO2002045753A2 (en) 2002-06-13
KR20040018314A (en) 2004-03-03
JP2004517083A (en) 2004-06-10
PL362445A1 (en) 2004-11-02
RU2003120446A (en) 2005-02-20
CZ20031589A3 (en) 2003-11-12
AR031461A1 (en) 2003-09-24
SK6942003A3 (en) 2003-10-07
IL155855A0 (en) 2003-12-23
HUP0401021A2 (en) 2004-09-28
AU2002226371A1 (en) 2002-06-18
CA2436692A1 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
RS52577B (en) Once-a-day oxycodone formulations
MX2009001711A (en) Sustained-release formulations of topiramate.
NO20050481L (en) Dosage form of pramipexole for once-daily dosing. day
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
NO20080827L (en) Solid dosage formulations of narcotic drugs that have improved buccal adsorption
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
MX2007000008A (en) Oral dosage form safeguarded against abuse containing (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
NO20070578L (en) Oral dosage form secured against abuse containing (1,2R) -3- (3-dimethylammino-1-ethyl-2-methyl-propyl) -phenol
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
BR9916361A (en) Controlled release tablet dosage form, controlled release tablet formulation, granular composition for pressing into a controlled release tablet dosage form, and methods for preparing a granular composition, for preparing a release tablet dosage form controlled use of divalproex sodium and to treat epilepsy
AR045289A1 (en) ORAL DOSAGE FORM OF CONTROLLED RELEASE THAT INCLUDES 4- (2-DI-N-PROPILAMINOETIL) - 2 (3H) -INDOLONE (ROPI-NIROL) AND USE OF SUCH DOSAGE FORM FOR THE PREPARATION OF A MEDICINAL PRODUCT
KR960010007A (en) Gephyron Dose Type
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
UA92498C2 (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
CA2416771A1 (en) 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid for treatment of cox-2 dependent disorders
KR910014128A (en) Pharmaceutical Compositions and Dosage Forms for Oral Administration of Calcitonin
NO20032581L (en) Pharmaceutical formulation of gepirone for oral administration
AP1485A (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin.
HUP0203148A2 (en) Orally distintegrating composition comprising mirtazapine
BR0207297A (en) Pharmaceutical composition in solid form and method of preparing a solid dosage form of a pharmaceutically active ingredient.
DE69803670D1 (en) MEDICINE PREPARATIONS WITH TIAGABINE WITH CONTROLLED ACTIVE SUBSTANCE ADMINISTRATION
KR20100124860A (en) Modified release composition comprising doxofylline
US6589996B2 (en) Treatment of disorders relating to the serotonergic system
KR20020089399A (en) Treatment of disorders relating to the serotonergic

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application